Guest Editor(s)
-
- Jia Fan, MD
- Department of Liver Surgery, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, Shanghai 200032, China.
Department of Molecular Cell Biology, Institute of Biomedical Sciences, Fudan University, Shanghai 200032, China.
E-mail
Special Issue Introduction
Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer, leading to more than 700 thousand deaths annually. In recent years, immunotherapy has emerged as a novel, effective systemic treatment for advanced HCC, which can potentially suppress tumor recurrence and metastasis. However, the objective response rate of simply immunologic agent treatment for HCC is still unsatisfactory. The combination of conventional treatments including stereotactic body radiation therapy (SBRT) with specific immunotherapeutic approaches may dramatically improve outcome of HCC patients. Moreover, the advancement of SBRT techniques has allowed for a safer administration of higher levels of dose to liver cancer while minimizing the potential liver toxicities. In this edition of Hepatoma Research, we will discuss new advances in SBRT, immunotherapy, and combined strategies for the treatment of patients with liver cancer.
Submission Deadline
30 Dec 2019
Hepatoma Research
hrjournal.net
